Entheon Biomedical Corp. announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for Human Drug Research (CHDR) to conduct an early phase human clinical trial with DMT. Based on an agreement signed October 7th, 2020, Entheon has contracted CHDR to carry out a study to evaluate the pharmacodynamics, pharmacokinetics and safety of a target- controlled intravenous infusion of N,N-dimethyltryptamine (DMT) (the "Product") in humans.